PPD Launches Innovative Technology Portal to Improve Patient Retention in Clinical Trials

PPD, Inc. (Nasdaq: PPDI) today announced it has launched an innovative online portal linking clinical trial participants with biopharmaceutical companies, physicians and health care resources to enhance patient connectivity and improve retention in clinical trials.

PPD PatientView is a secure online technology empowering clinical trial participants to view, share and electronically archive medical information related to their illness, enabling them toplay a more active role in managing their health and actively engaging them throughout the duration of a clinical trial.

"Regulatory agencies are requiring longer, more complex clinical studies, increasing the likelihood of patients leaving a clinical study before it´s completed," said Mike Wilkinson, executive vice president and chief information officer for PPD. "The loss of patients during a trial can lead to increased costs and delay the trial´s completion. PPD PatientView empowers patients by enabling better communication with the study team, better connectivity with study activities and better access to information about their individual disease."

PPD PatientView is customizable, allows patients online access to valuable health information and is a convenient way to stay in continual contact with the trial registry and monitoring program. The portal leverages Microsoft HealthVault, a personal health application platform that lets consumers gather, store and share health information online.

"PPD PatientView also provides patients access to the personal data they are contributing to the study on a per-visit basis," said Dave Agrella, executive director for customer solutions for PPD. "We believe this kind of access increases their sense of involvement and engagement in contributing to the development of best-in-class medicines for their disease and ultimately improves the likelihood that they will remain in the trial until its completion."

PPD PatientView is a part of PPD ® Adaptive Solutions, the suite of customizable, flexible and integrated technology solutions that PPD deploys to meet each client´s needs in advancing their research initiatives. PPD and Microsoft have announced plans to jointly implement an innovative technology solution to improve efficiency in managing U.S.

Food and Drug Administration-mandated Risk Evaluation and Mitigation Strategy (REMS) programs. PPD also was recognized on the 2010 InformationWeek 500, a list of the nation´s most innovative users of business technology.

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com

Suggested Articles

After seeing later stage trials come through in obesity, Novo Nordisk is canning two projects that were aiming to help reduce patients’ weight.

T-knife has raised €66 million ($78 million) to take four prospects from its TCR-T-cell platform into the clinic in solid tumor indications.

The NIH is starting with Eli Lilly and AbCellera's COVID-19 antibody but could add more prospects as the trial goes on.